Gastro-esophageal Reflux Disease (GERD) Completed Phase 3 Trials for Alginic acid (DB13518)

Also known as: Esophageal Reflux / Gastroesophageal Reflux Disease / Gastrooesophageal reflux disease / Gastro-Oesophageal Reflux Disease / Gastro-esophageal Reflux Disease / Gastro-esophageal Reflux Diseases / GERD Gastroesophageal Reflux Disease / GERD (Gastroesophageal Reflux Disease) / GERD / GERD - Gastro-Esophageal Reflux Disease / Gastroesophageal Reflux Disease (GERD) / Oesophageal reflux / Esophagitis / Gastrooesophageal reflux / Gastroesophageal reflux / Esophageal reflux NOS

IndicationStatusPhase
DBCOND0077290 (Gastro-esophageal Reflux Disease (GERD))Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01338077Efficacy and Safety of Sodium Alginate Oral Suspension to Treat Non-erosive Gastro-esophageal Reflux DiseaseTreatment
NCT01869491Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief StudyTreatment
NCT01872897Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD PatientsTreatment
NCT02623062Compound Sodium Alginate Oral Suspension Sachet Symptomatic Relief StudyTreatment